Logo
  • ABOUT US
  • PIPELINE & PUBLICATIONS
  • Investor Overview
  • NEWS
Menu Trigger
  • ABOUT US
  • PIPELINE & PUBLICATIONS
  • Investor Overview
  • NEWS
  • Corporate Governance
  • Careers
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Jul 18, 2022 8:00am EDT

Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL001 Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder

Jun 03, 2022 8:00am EDT

Alzamend Neuro to Present at the 12th Annual LD Micro Invitational

May 17, 2022 8:00am EDT

Alzamend Neuro Announces Pre-IND Submission for AL001 as a Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder

May 05, 2022 8:00am EDT

Alzamend Neuro Announces Initiation of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s

Apr 28, 2022 6:30am EDT

Alzamend Neuro Announces $4 Million Additional Investment from Digital Power Lending Upon Completion of Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s

Apr 11, 2022 8:00am EDT

Alzamend Neuro Contracts with Altasciences and iResearch Atlanta to Manage and Conduct Its Phase IIA Study in Patients with Alzheimer’s

Apr 04, 2022 8:00am EDT

Alzamend Neuro Appoints Dr. Terri Hunter to Its Scientific Advisory Board

Mar 28, 2022 8:00am EDT

Alzamend Neuro Announces Full Data Set From Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s

Dec 17, 2021 9:00am EST

Alzamend Neuro Announces Positive Topline Data from Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s

Nov 30, 2021 8:30am EST

Alzamend Neuro Announces Date for Delivery of Topline Data for Phase 1 First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer’s

  • 1
  • 2
  • 3
  • 4
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
Logo
  • Facebook
  • Twitter
  • Alzamend Neuro is a registered mark of Alzamend Neuro Inc.
  • © Copyright 2016 - 2022 | All rights reserved. | Terms of Use